



Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call

November 5, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 5, 2019-- [Tetraphase Pharmaceuticals, Inc.](#) (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will host a conference call at 4:30 p.m. ET on Tuesday, November 12, 2019 to discuss the Company's third quarter 2019 financial results and provide a general corporate update.

The conference call may be accessed by dialing 844-831-4023 (U.S. and Canada) or 731-256-5215 (international) and entering conference ID number 2362909. A live audio webcast of the conference call will be available online from the "Investors – Events & Presentations" section of the Tetraphase website at www.tphase.com.

A replay of the conference call will be available from 7:30 p.m. ET on Tuesday, November 12, 2019, through 7:30 p.m. ET on Tuesday, November 19, 2019 by dialing 855-859-2056 (U.S. and Canada) and 404-537-3406 for (international) callers. The conference ID number is 2362909. A replay of the webcast will be available by visiting Tetraphase's website.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company's pipeline also includes antibiotics TP-271 and TP-6076, which are Phase 2 ready, and TP-2846, which is in preclinical testing for acute myeloid leukemia. The Company intends to out license its pipeline candidates. Please visit www.tphase.com for more company information.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191105005148/en/>

Source: Tetraphase Pharmaceuticals, Inc.

Media and Investor Contact:

Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com